GSE155162 GSE155169 buparlisib 1 v 3 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE155162_GSE155169_buparlisib_1_v_3_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE155162_GSE155169_buparlisib_1_v_3_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE155162_GSE155169_buparlisib_1_v_3_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE155162_GSE155169_buparlisib_1_v_3_human_up.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 1

Gene

multidrug resistance-related protein

Gene

long intergenic non-protein coding RNA 511

Gene

long intergenic non-protein coding RNA 3219

Gene

LOXL1 antisense RNA 1

Gene

HERPUD2 antisense RNA 1

Gene

WAP four-disulfide core domain 21, pseudogene

Gene

AGAP2 antisense RNA 1

Gene

HOXA10 antisense RNA

Gene

ACTA2 antisense RNA 1

  • Gene

    small nucleolar RNA host gene 1


  • Gene

    multidrug resistance-related protein


  • Gene

    long intergenic non-protein coding RNA 511


  • Gene

    long intergenic non-protein coding RNA 3219


  • Gene

    LOXL1 antisense RNA 1


  • Gene

    HERPUD2 antisense RNA 1


  • Gene

    WAP four-disulfide core domain 21, pseudogene


  • Gene

    AGAP2 antisense RNA 1


  • Gene

    HOXA10 antisense RNA


  • Gene

    ACTA2 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.